M&A Deal Summary

OncoCyte Acquires Insight Genetics

On January 10, 2020, OncoCyte acquired life science company Insight Genetics for 12M USD

Acquisition Highlights
  • This is OncoCyte’s 1st transaction in the Life Science sector.
  • This is OncoCyte’s largest (disclosed) transaction.
  • This is OncoCyte’s 1st transaction in the United States.
  • This is OncoCyte’s 1st transaction in Tennessee.

M&A Deal Summary
Date 2020-01-10
Target Insight Genetics
Sector Life Science
Buyer(s) OncoCyte
Deal Type Add-on Acquisition
Deal Value 12M USD

Target

Insight Genetics

Nashville, Tennessee, United States
Insight Genetics, Inc. is a provider of molecular diagnostics that enable precision cancer care. Insight Genetics was founded in 2005 and is based in Nashville, Tennessee.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

OncoCyte

Irvine, California, United States
Category Company
Founded 2009
Sector Life Science
Employees43
Revenue 1M USD (2023)
DESCRIPTION

OncoCyte is a molecular diagnostics company. OncoCyte was founded in 2009 and is based in Irvine, California.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 2
State (Tennessee) 1 of 1
Country (United States) 1 of 2
Year (2020) 1 of 2
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-10-01 Chronix Biomedical

San Jose, California, United States

Chronix Biomedical is a molecular diagnostics company developing blood tests for use in cancer treatment and organ transplantation. Chronix’s TheraSure CNI Monitor for cancer uses proprietary algorithms to derive a copy number instability (CNI) score from the sequencing of circulating cell-free tumor DNA (cfDNA), which can be used in the prognosis, diagnosis, and monitoring of therapeutic response to cancer. Chronix TheraSure™ Transplant Monitor quantifies the amount of graft-derived cell-free DNA in organ recipients to detect early rejection of organ transplants and better assess the transplant health. Chronix Biomedical was founded in 1997 and is based in San Jose, California.

Buy -
Mergr

Product

Company

Legal